If you look at the mechanisms of action, you can look at the ones speficiflly through CCR5. That is why it is important to be ccr5/ccl5 pathway and not possibly through other receptors. This is what the big pharmacy and investors haven't realized yet imo. The cancer data in human trial coming out will make them notice it is different with ccr5/ccl5 because it has some unique mechanisms of action, where the other in the past have failed due to multiple mechanisms of action, they blocked one receptor and it continued to work through another. Which in my opinion we haven't seen the excitement yet because of past failures have dampened their expectations.


https://investorshangout.com/post/view?id=5506865


For example the DNA Damage repair is unique to ccr5. Block that and cancer cells can't repair as quick.


CCR5 Governs DNA Damage Repair and BreastCancer Stem Cell Expansion

https://content.equisolve.net/_5dde3bf0adc368...R.full.pdf